Skip to main content

Table 2 Frequency of drug use in MS patients

From: Polypharmacy in patients with multiple sclerosis: a gender-specific analysis

Drugs

Female (N = 218)

Male (N = 88)

p valueFi

FDRFi

Frequency of medication groupsc

Frequency of medication groupsc

DMDs

92.7%

90.9%

0.641

0.859

Gastrointestinal drugs

42.7%

45.5%

0.703

0.859

Thrombosis prophylactics

37.6%

45.5%

0.246

0.673

Osteoporosis drugs

34.4%

37.5%

0.692

0.859

Dietary supplements

33.9%

23.9%

0.101

0.556

Sedatives

30.7%

23.9%

0.265

0.673

Analgesics

28.0%

20.5%

0.196

0.673

Antihypertensives

23.9%

28.4%

0.467

0.835

Thyroid drugs

20.2%

1.1%

< 0.001

< 0.001

Antidepressants

19.7%

15.9%

0.518

0.835

Aconuresis drugs

18.8%

18.2%

1.000

1.000

Antispasmodics

17.9%

31.8%

0.010

0.110

Anticonvulsants

16.5%

18.2%

0.738

0.869

Contraceptives

16.1%

0.0%

< 0.001

< 0.001

Common cold remedies

11.9%

8.0%

0.416

0.808

Antiinfectives

8.7%

4.5%

0.242

0.673

Cholesterol-lowering drugs

6.9%

11.4%

0.248

0.673

Fampridine

6.0%

14.8%

0.021

0.173

Diabetes drugs

5.5%

3.4%

0.567

0.835

Antiallergics

5.0%

2.3%

0.361

0.794

Anti-Parkinson drugs

5.0%

3.4%

0.764

0.869

Menopause medications

5.0%

0.0%

0.038

0.251

Eye drops

4.6%

1.1%

0.187

0.673

Asthma drugs

2.3%

1.1%

0.677

0.859

Dermatics

2.3%

0.0%

0.326

0.768

Antidementives

1.8%

0.0%

0.582

0.835

IT for comorbidities

1.8%

3.4%

0.414

0.808

Migraine medications

1.4%

0.0%

0.560

0.835

Neuroleptics

1.4%

0.0%

0.560

0.835

Antivertiginous drugs

0.9%

0.0%

1.000

1.000

Fatigue drugs

0.5%

2.3%

0.200

0.673

Uricostatics

0.5%

0.0%

1.000

1.000

VRA

0.5%

0.0%

1.000

1.000

  1. DMDs disease-modifying drugs, FDR adjusted p value according to false discovery rate, IT immunotherapy, N number of patients, VRA vasopressin receptor antagonists
  2. cProportion of patients in %
  3. FiFisher’s exact test